tracker

Table of Contents for Therapeutic/Diagnostic Devices for Neurological Disorders



Paper - USD 4250.00  
Single-user PDF - USD 4850.00  
PDF Site License - USD 5950.00  
PDF Corporate License - USD 8500.00  


TABLE OF CONTENTS

INTRODUCTION

 xix

STUDY GOALS AND OBJECTIVES

xix

REASONS FOR DOING THE STUDY

xix

AUDIENCE FOR THE REPORT

xx

SCOPE AND FORMAT

xx

METHODOLOGY AND INFORMATION SOURCES

xxi

ABOUT THE AUTHOR

xxi

BCC INFORMATION AND RELATED BCC STUDIES

xxi

DISCLAIMER

xxii

BCC RESEARCH ONLINE SERVICES

xxii

EXECUTIVE SUMMARY

 xxiv

Summary Table:
GLOBAL MARKET FORECAST FOR BRANDED MEDICATIONS FOR NEURODEGENERATIVE DISORDERS, THROUGH 2012 ($ MILLIONS)

XXIV

Summary Figure:
GLOBAL MARKET FORECAST FOR BRANDED MEDICATIONS FOR NEURODEGENERATIVE DISORDERS, 2006-2012 ($ MILLIONS

XXV

OVERVIEW

 1

GOVERNMENT REGULATIONS

1

INTRODUCTION

1

DRUG DISCOVERY

2

PRECLINICAL TESTING AND SUBMISSION OF AN IND

3

CLINICAL TRIALS

4

TIMELINE AND COSTS

5

SUBMISSION OF AN NDA OR BLA

5

POST-FDA APPROVAL

6

NEW DRUG APPROVALS

7

Table 1 DRUGS APPROVED BY THE FDA, 1993-1999

7

Table 2 DRUGS APPROVED BY THE FDA, 2000-2006

7

Table 3 NEW MOLECULAR/BIOLOGICAL ENTITIES APPROVED BY THE FDA, 1980-2006

8

CONCLUSIONS

9

Table 4 NME APPROVALS FOR NEUROLOGICAL DISORDERS, 2004-2006

9

Conclusions (Continued)

10

THE U.S. MARKETS FOR ALZHEIMER'S DISEASE MEDICATIONS

 11

ABOUT ALZHEIMER'S DISEASE

11

Table 5 GLOBAL MARKET FORECAST FOR ALZHEIMER'S DISEASE PHARMACEUTICALS, THROUGH 2012 ($ MILLIONS)

11

Figure 1 GLOBAL MARKET FORECAST FOR ALZHEIMER'S DISEASE PHARMACEUTICALS, 2005-2012 ($ MILLIONS)

11

ABOUT ALZHEIMER'S DISEASE (CONTINUED)

12

CURRENT BRANDED PHARMACEUTICALS THAT TREAT ALZHEIMER'S DISEASE

13

ARICEPT (DONEPEZIL HCL)

13

Table 6 GLOBAL MARKET FORECAST FOR ARICEPT SALES, THROUGH 2012 ($ MILLIONS)

13

Acetylcholinesterase Inhibitors

13

Generic Competition

14

COGNEX (TACRINE HYDROCHLORIDE)

15

Table 7 GLOBAL MARKET FORECAST FOR COGNEX SALES, THROUGH 2012 ($ MILLIONS)

15

EBIXA, NAMENDA, AND AXURA (MEMANTINE HYDROCHLORIDE)

16

Table 8 GLOBAL MARKET FORECAST FOR MEMANTINE SALES, THROUGH 2012 ($ MILLIONS)

16

NMDA Antagonists

17

Patent Protection and Second-Generation NMDA Antagonists

17

Table 9 NMDA ANTAGONISTS IN CLINICAL TRIALS

18

EXELON (RIVASTIGMINE TARTRATE)

18

Table 10 GLOBAL MARKET FORECAST FOR AD-RELATED EXELON SALES, THROUGH 2012 ($ MILLIONS)

19

RAZADYNE (GALANTAMINE HYDROBROMIDE)

19

Table 11 GLOBAL MARKET FORECAST FOR RAZADYNE SALES, THROUGH 2012 ($ MILLIONS)

20

COMPOUNDS IN CLINICAL TRIALS FOR AD

20

Table 12 POTENTIAL AD AGENTS IN PHASE III CLINICAL TRIALS

21

Alzhemed

21

Flurizan

22

Neramexane

22

Phenserine

22

Failed AD Candidate Drugs

23

COMPANY PROFILES

23

FOREST LABORATORIES

23

MEDIVATION

24

MERZ PHARMA GMBH & CO. KGAA

24

NEUROCHEM, INC.

25

SCIELE PHARMA, INC.

26

THE U.S. MARKETS FOR MEDICATIONS DIRECTED AT AMYOTROPHIC LATERAL SCLEROSIS

 27

Table 13 GLOBAL MARKET FORECAST FOR ALS THERAPEUTICS, THROUGH 2012 ($ MILLIONS)

27

Figure 2 GLOBAL MARKET FORECAST FOR ALS THERAPEUTICS, 2005-2012 ($ MILLIONS)

27

THE U.S. MARKETS (CONTINUED)

28

ALS: BACKGROUND INFORMATION

29

ALS: BACKGROUND … (CONTINUED)

30

RILUTEK: THE SOLE FDA-APPROVED DRUG FOR ALS

30

Table 14 U.S. MARKET FORECAST FOR RILUTEK, THROUGH 2012 ($ MILLIONS)

31

ANIMAL MODELS OF ALS AND PRECLINICAL STUDIES

32

STRENGTHS OF RODENT ALS MODELS

32

LIMITATIONS OF RODENT ALS MODELS

33

Table 15 ALS/SOD1 RODENT MODELS

33

ALS DRUG CANDIDATES IN CLINICAL TRIALS

34

SURVIVAL

35

Table 16 A SAMPLE OF ALS DRUG CANDIDATES IN CLINICAL TRIALS

36

Table 17 ALS DRUG CANDIDATES FOR WHICH NDAS HAVE BEEN FILED WITH THE FDA

37

Table 18 ALS DRUG CANDIDATES THAT PEFORMED WELL IN CLINICAL TRIALS

37

Table 19 A SAMPLE OF RECENT ALS DRUG CANDIDATES THAT DID NOT PEFORM WELL IN CLINICAL TRIALS

38

Table 19 (CONTINUED)

39

CURRENT COLLABORATIONS AND DRUG DISCOVERY PROGRAMS IN ALS DRUG DISCOVERY OR DEVELOPMENT

39

Table 20 ALS DRUG CANDIDATES IN PRECLINICAL DEVELOPMENT

40

AEOLUS PHARMACEUTICALS

40

BIOGEN IDEC AND AMORFIX LIFE SCIENCES

40

ISIS PHARMACEUTICALS

41

METABOLON

41

POWER3 MEDICAL PRODUCTS

41

DIAGNOSTIC PRODUCTS FOR ALS

42

Table 21 U.S. MARKETFORECAST FOR ALS DIAGNOSTIC PRODUCTS, THROUGH 2012 ($ MILLIONS)

42

Table 22 RESEARCH EFFORTS AIMED AT BIOMARKERS FOR ALS

43

COMPANY PROFILES

43

AEOLUS PHARMACEUTICALS

43

AMORFIX LIFE SCIENCES

44

AVICENA GROUP, INC.

44

CYTRX CORP.

45

ISIS PHARMACEUTICALS, INC.

46

METABOLON

47

POWER3 MEDICAL PRODUCTS

48

MARKETS FOR MEDICATIONS DIRECTED AT HUNTINGTON'S DISEASE

 49

Table 23 GLOBAL MARKET FORECAST FOR HUNTINGTON'S DISEASE THERAPEUTIC AGENTS, THROUGH 2012 ($ MILLIONS)

49

Figure 3 GLOBAL MARKET FORECAST FOR HUNTINGTON'S DISEASE THERAPEUTIC AGENTS, 2006-2012 ($ MILLIONS)

50

HUNTINGTON'S DISEASE: BACKGROUND INFORMATION

51

TETRABENAZINE LIKELY THE FIRST PRODUCT TO GAIN FDA APPROVAL FOR HUNTINGTON'S DISEASE

52

Table 24 GLOBAL MARKET FORECAST FOR THE U.S. AND WORLDWIDE SALES FOR TETRABENAZINE, THROUGH 2012 ($ MILLIONS)

53

HD DRUG CANDIDATES IN CLINICAL TRIALS

53

Table 25 HD DRUG CANDIDATES IN CLINICAL TRIALS

54

MIRAXION

54

DIMEBON

54

CREATINE/HD-02

55

MINOCYCLINE

55

OTHER AGENTS IN CLINICAL TRIALS FOR HD

56

COMPANY PROFILES

56

AMARIN CORP., PLC

56

AVICENA GROUP, INC.

57

MEDIVATION

57

PRESTWICK PHARMACEUTICALS

58

Prestwick Pharmaceuticals (Continued)

59

MARKETS FOR MEDICATIONS DIRECTED AT MULTIPLE SCLEROSIS

 60

Table 26 GLOBAL MARKET FORECAST FOR MULTIPLE SCLEROSIS THERAPEUTICS, THROUGH 2012 ($ MILLIONS)

60

Figure 4 GLOBAL MARKET FORECAST FOR MULTIPLE SCLEROSIS THERAPEUTICS, 2005-2012 ($ MILLIONS)

60

ABOUT MS

61

Table 27 OVERALL MARKET LEADERS IN MS THERAPEUTIC AGENTS, 2005 AND 2006 ($ MILLIONS)

62

Table 28 U.S. MARKET LEADERS IN MS THERAPEUTICS, 2006 AND 2006 ($ MILLIONS)

63

CURRENT PHARMACEUTICAL AGENTS THAT TREAT MULTIPLE SCLEROSIS

64

AVONEX

64

Table 29 GLOBAL MARKET FORECAST FOR AVONEX SALES, THROUGH 2012 ($ MILLIONS)

64

Table 30 U.S. AVONEX SALES AS A PERCENTAGE OF TOTAL SALES, 2003-2012 (PERCENT (%) ROUNDED TO THE NEAREST WHOLE VALUE)

65

Factors Affecting Avonex Sales

65

BETASERON

66

Table 31 GLOBAL MARKET FORECAST FOR BETASERON, THROUGH 2012 ($ MILLIONS)

67

Table 32 U.S. BETASERON SALES AS A PERCENTAGE OF TOTAL SALES, 2003-2012 (ROUNDED TO THE NEAREST WHOLE VALUE)

68

Factors Affecting Sales of Betaseron

68

Generic competition

68

Cross-Border Sales in the European Union

69

Tysabri

69

COPAXONE

69

Table 33 GLOBAL MARKET FORECAST FOR COPAXONE, THROUGH 2012 ($ MILLIONS)

70

Table 34 U.S. COPAXONE SALES AS A PERCENTAGE OF TOTAL SALES, 2003-2012 (PERCENT (%) ROUNDED TO THE NEAREST WHOLE VALUE)

71

Factors Affecting Copaxone's Future Revenues

71

NOVANTRONE (MITOXANTRONE)

72

Table 35 MARKET FORECAST FOR BRAND-NAME NOVANTRONE, THROUGH 2012 ($ MILLIONS)

72

REBIF

73

Table 36 GLOBAL MARKET FORECAST FOR REBIF, THROUGH 2012 ($ MILLIONS)

73

Table 37 U.S. REBIF SALES AS A PERCENTAGE OF TOTAL SALES, 2003-2012 (PERCENT (%) ROUNDED TO THE NEAREST WHOLE VALUE)

74

Factors Affecting Rebif's Future Revenues

74

TYSABRI

75

Table 38 GLOBAL MARKET FORECAST FOR TYSABRI, THROUGH 2012 ($ MILLIONS)

76

Tysabri (Continued)

77

MS DRUG CANDIDATES IN CLINICAL TRIALS

78

Table 39 A SAMPLE OF MS DRUG CANDIDATES IN CLINICAL TRIALS

78

EARLY STAGE COLLABORATIONS IN MS

79

Early Stage Collaborations … (Continued)

80

COMPANY PROFILES

81

BIOGEN IDEC

81

CHEMOCENTRYX, INC.

82

PARATEK PHARMACEUTICALS

82

PDL BIOPHARMA, INC.

83

SERONO INTERNATIONAL SA

84

Serono, Inc.

84

SYNTONIX PHARMACEUTICALS, INC.

85

TEVA PHARMACEUTICALS

86

Teva North America

86

Teva … (Continued)

87

MARKETS FOR MEDICATIONS DIRECTED AT PARKINSON'S DISEASE

 88

Table 40 GLOBAL MARKET FORECAST FOR PARKINSON'S DISEASE THERAPEUTICS, THROUGH 2012 ($ MILLIONS)

88

Figure 5 GLOBAL MARKET FORECAST FOR PARKINSON'S DISEASE THERAPEUTICS, 2005-2012 ($ MILLIONS)

88

CHARACTERISTICS OF THE PARKINSON'S DISEASE THERAPEUTICS INDUSTRY

89

ABOUT PARKINSON'S DISEASE

90

SHORTCOMINGS OF LEVODOPA THERAPY AND NEW MEDICATIONS

91

IMPROVEMENTS TO LEVODOPA MONOTHERAPY

91

Dopamine Agonists

92

Anticholinergics

92

MAO-B inhibitors

92

COMT Inhibitors

93

CURRENT BRANDED PHARMACEUTICAL AGENTS THAT TREAT PD

93

APOKYN/ APOMORPHINE

93

Table 41 GLOBAL MARKET FORECAST FOR APOKYN/APOMORPHINE, THROUGH 2012 ($ MILLIONS)

94

INJECTABLE APOMORPHINE: BARRIERS TO MARKET PENETRATION

95

AZILECT (RASAGILINE)

96

Table 42 GLOBAL MARKET FORECAST FOR AZILECT, THROUGH 2012 ($ MILLIONS)

96

MIRAPEX (PRAMIPEXOLE)

97

Table 43 GLOBAL MARKET FORECAST FOR MIRAPEX, THROUGH 2012 ($ MILLIONS)

97

MIRAPEX AND COMPULSIVE BEHAVIORS

98

MIRAPEX AND RESTLESS LEGS SYNDROME

98

REQUIP (ROPINIROLE HYDROCHLORIDE)

99

Table 44 GLOBAL MARKET FORECAST FOR REQUIP FOR PARKINSON'S DISEASE, THROUGH 2012 ($ MILLIONS)

99

Table 45 U.S. PD-RELEATED REQUIP SALES AS A PERCENTAGE OF TOTAL SALES, 2004-2012 (PERCENT (%) ROUNDED TO THE NEAREST WHOLE VALUE)

100

REQUIP AND COMPULSIVE BEHAVIORS

100

STALEVO AND COMTAN

100

Table 46 GLOBAL MARKET FORECAST FOR COMTAN/STALEVO, THROUGH 2012 ($ MILLIONS)

101

TASMAR (TOLCAPONE)

102

Table 47 GLOBAL MARKET FORECAST FOR TASMAR, THROUGH 2012 ($ MILLIONS)

102

ZELAPAR (SELEGILINE HCL)

103

Table 48 GLOBAL MARKET FORECAST FOR ZELAPAR, THROUGH 2012 ($ MILLIONS)

104

PD DRUG CANDIDATES IN CLINICAL TRIALS

104

Table 49 A SAMPLE OF PD DRUG CANDIDATES IN CLINICAL TRIALS

105

E2007

105

Direct-to-the-Brain Drug Delivery

106

COMPANY PROFILES

106

ORION PHARMACEUTICALS

106

TEVA PHARMACEUTICALS

107

Teva North America

107

VALEANT PHARMACEUTICALS

108

VERNALIS, PLC

109

MARKETS FOR MEDICATIONS DIRECTED AT MUSCULAR DYSTROPHY AND RARE NEURODEGENERATIVE DISORDERS

 110

Table 50 GLOBAL MARKET FORECAST FOR MUSCULAR DYSTROPHY-RELATED THERAPEUTIC AGENTS, THROUGH 2011 ($ MILLIONS)

110

Figure 6 GLOBAL MARKET FORECAST FOR MUSCULAR DYSTROPHY-RELATED THERAPEUTIC AGENTS, 2005- 2021 ($ MILLIONS)

111

THE MUSCULAR DYSTROPHIES

112

BACKGROUND INFORMATION

112

MD DRUG CANDIDATES IN CLINICAL TRIALS

113

Table 51 MD DRUG CANDIDATES IN CLINICAL TRIALS

114

PTC124

114

Stamulumab

115

Other Agents in Clinical Trials for MD

116

RARE NEURODEGENERATIVE DISORDERS

116

Table 52 GLOBAL MARKET FORECAST FOR RARE NEURODEGENERATIVE DISORDERS, THROUGH 2012 ($ MILLIONS)

117

Figure 7 GLOBAL MARKET FORECAST FOR RARE NEURODEGENERATIVE DISORDERS, 2005-2012 ($ MILLIONS)

117

CANDIDATES FOR RARE NEURODEGENERATIVE DISORDERS IN CLINICAL TRIALS

118

Table 53 CANDIDATES IN CLINICAL TRIALS FOR RARE DISORDERS

118

Batten Disease

118

Niemann-Pick Disease

119

Adrenoleukodystrophy

120

Lorenzo's Oil

120

COMPANY PROFILES

120

GENZYME

120

Genzyme (Continued)

121

PTC THERAPEUTICS

122

STEM CELLS, INC.

123

WYETH PHARMACEUTICALS

123

Wyeth Pharmaceuticals (Continued)

124

U.S. PATENT ANALYSIS

 125

INTRODUCTION

125

AMYOTROPHIC LATERAL SCLEROSIS (ALS)

125

Table 54 ALS-RELATED TECHNOLOGY: U.S. PATENT TRENDS, 1997-2007*

126

Table 55 ALS-RELATED PATENTS BY USE CATEGORY

126

GENERAL TRENDS

127

TRENDS BY ASSIGNEE

127

Table 56 ALS-RELATED PATENTS BY ASSIGNEE CATEGORY

127

Table 56 (CONTINUED)

128

Table 57 ALS-RELATED PATENTS BY COMPANY

129

PATENT APPLICATION TRENDS

129

Table 58 ALS-RELATED PATENT APPLICATIONS BY USE CATEGORY

130

Table 59 ALS-RELATED TECHNOLOGY: U.S. PATENT APPLICATION TRENDS, 2001-2006

131

TRENDS BY COUNTRY

131

HUNTINGTON'S DISEASE (HD)

132

Table 60 HUNTINGTON'S DISEASE-RELATED TECHNOLOGY: U.S. PATENT TRENDS, 1997-2007

132

Table 61 HD-RELATED PATENTS BY USE CATEGORY

133

TRENDS BY ASSIGNEE

133

Table 62 HD-RELATED PATENTS BY ASSIGNEE CATEGORY

134

Table 63 HD-RELATED PATENTS BY COMPANY

135

ALZHEIMER'S DISEASE (AD)

135

Table 64 ALZHEIMER'S DISEASE-RELATED TECHNOLOGY: U.S. PATENT TRENDS, 1997-2007

135

Table 65 AD-RELATED PATENTS BY USE CATEGORY

136

TRENDS BY ASSIGNEE

137

Table 66 AD-RELATED PATENTS BY ASSIGNEE CATEGORY

137

Table 67 AD-RELATED PATENTS BY COMPANY

138

PARKINSON'S DISEASE (PD)

138

Table 68 PARKINSON'S DISEASE-RELATED TECHNOLOGY: U.S. PATENT TRENDS, 1997-2007

139

Table 69 PD-RELATED PATENTS BY USE CATEGORY

140

TRENDS BY ASSIGNEE

140

Table 70 PD-RELATED PATENTS BY ASSIGNEE CATEGORY

141

Table 71 PD-RELATED PATENTS BY COMPANY

142

MULTIPLE SCLEROSIS (MS)

142

Table 72 MULTIPLE SCLEROSIS-RELATED TECHNOLOGY: U.S. PATENT TRENDS, 1997-2007

143

Table 73 MS-RELATED PATENTS BY USE CATEGORY

143

TRENDS BY ASSIGNEE

144

Table 74 MS-RELATED PATENTS BY ASSIGNEE CATEGORY

144

Table 75 MS-RELATED PATENTS BY COMPANY

145

MUSCULAR DYSTROPHY (MD)

146

Table 76 MUSCULAR DYSTROPHY-RELATED TECHNOLOGY: U.S. PATENT TRENDS, 1997-2007

146

Table 77 MD-RELATED PATENTS BY USE CATEGORY

147

TRENDS BY ASSIGNEE

147

Table 78 MD-RELATED PATENTS BY ASSIGNEE CATEGORY

148

Table 79 MD-RELATED PATENTS BY ORGANIZATION

149

MD-RELATED PATENT APPLICATIONS

149

Table 80 MUSCULAR DYSTROPHY-RELATED TECHNOLOGY: U.S. PATENT APPLICATION TRENDS, 2001-2007

149

Table 81 MD-RELATED PATENT APPLICATIONS BY USE CATEGORY

150

A RARE DISORDER: ATAXIA-TELANGIECTASIA

150

Table 82 RARE DISORDER PATENT APPLICATIONS BY DISEASE

150

Table 83 ATAXIA-TELANGIECTASIA-RELATED PATENTS BY USE CATEGORY

151
   

LIST OF TABLES

  

Summary Table:
GLOBAL MARKET FORECAST FOR BRANDED MEDICATIONS FOR NEURODEGENERATIVE DISORDERS, THROUGH 2012 ($ MILLIONS)

 xxiv

Table 1 DRUGS APPROVED BY THE FDA, 1993-1999

 7

Table 2 DRUGS APPROVED BY THE FDA, 2000-2006

 7

Table 3 NEW MOLECULAR/BIOLOGICAL ENTITIES APPROVED BY THE FDA, 1980-2006

 8

Table 4 NME APPROVALS FOR NEUROLOGICAL DISORDERS, 2004-2006

 9

Table 5 GLOBAL MARKET FORECAST FOR ALZHEIMER'S DISEASE PHARMACEUTICALS, THROUGH 2012 ($ MILLIONS)

 11

Table 6 GLOBAL MARKET FORECAST FOR ARICEPT SALES, THROUGH 2012 ($ MILLIONS)

 13

Table 7 GLOBAL MARKET FORECAST FOR COGNEX SALES, THROUGH 2012 ($ MILLIONS)

 15

Table 8 GLOBAL MARKET FORECAST FOR MEMANTINE SALES, THROUGH 2012 ($ MILLIONS)

 16

Table 9 NMDA ANTAGONISTS IN CLINICAL TRIALS

 18

Table 10 GLOBAL MARKET FORECAST FOR AD-RELATED EXELON SALES, THROUGH 2012 ($ MILLIONS)

 19

Table 11 GLOBAL MARKET FORECAST FOR RAZADYNE SALES, THROUGH 2012 ($ MILLIONS)

 20

Table 12 POTENTIAL AD AGENTS IN PHASE III CLINICAL TRIALS

 21

Table 13 GLOBAL MARKET FORECAST FOR ALS THERAPEUTICS, THROUGH 2012 ($ MILLIONS)

 27

Table 14 U.S. MARKET FORECAST FOR RILUTEK, THROUGH 2012 ($ MILLIONS)

 31

Table 15 ALS/SOD1 RODENT MODELS

 33

Table 16 A SAMPLE OF ALS DRUG CANDIDATES IN CLINICAL TRIALS

 36

Table 17 ALS DRUG CANDIDATES FOR WHICH NDAS HAVE BEEN FILED WITH THE FDA

 37

Table 18 ALS DRUG CANDIDATES THAT PEFORMED WELL IN CLINICAL TRIALS

 37

Table 19 A SAMPLE OF RECENT ALS DRUG CANDIDATES THAT DID NOT PEFORM WELL IN CLINICAL TRIALS

 38

Table 20 ALS DRUG CANDIDATES IN PRECLINICAL DEVELOPMENT

 40

Table 21 U.S. MARKETFORECAST FOR ALS DIAGNOSTIC PRODUCTS, THROUGH 2012 ($ MILLIONS)

 42

Table 22 RESEARCH EFFORTS AIMED AT BIOMARKERS FOR ALS

 43

Table 23 GLOBAL MARKET FORECAST FOR HUNTINGTON'S DISEASE THERAPEUTIC AGENTS, THROUGH 2012 ($ MILLIONS)

 49

Table 24 GLOBAL MARKET FORECAST FOR THE U.S. AND WORLDWIDE SALES FOR TETRABENAZINE, THROUGH 2012 ($ MILLIONS)

 53

Table 25 HD DRUG CANDIDATES IN CLINICAL TRIALS

 54

Table 26 GLOBAL MARKET FORECAST FOR MULTIPLE SCLEROSIS THERAPEUTICS, THROUGH 2012 ($ MILLIONS)

 60

Table 27 OVERALL MARKET LEADERS IN MS THERAPEUTIC AGENTS, 2005 AND 2006 ($ MILLIONS)

 62

Table 28 U.S. MARKET LEADERS IN MS THERAPEUTICS, 2006 AND 2006 ($ MILLIONS)

 63

Table 29 GLOBAL MARKET FORECAST FOR AVONEX SALES, THROUGH 2012 ($ MILLIONS)

 64

Table 30 U.S. AVONEX SALES AS A PERCENTAGE OF TOTAL SALES, 2003-2012 (PERCENT (%) ROUNDED TO THE NEAREST WHOLE VALUE)

 65

Table 31 GLOBAL MARKET FORECAST FOR BETASERON, THROUGH 2012 ($ MILLIONS)

 67

Table 32 U.S. BETASERON SALES AS A PERCENTAGE OF TOTAL SALES, 2003-2012 (ROUNDED TO THE NEAREST WHOLE VALUE)

 68

Table 33 GLOBAL MARKET FORECAST FOR COPAXONE, THROUGH 2012 ($ MILLIONS)

 70

Table 34 U.S. COPAXONE SALES AS A PERCENTAGE OF TOTAL SALES, 2003-2012 (PERCENT (%) ROUNDED TO THE NEAREST WHOLE VALUE)

 71

Table 35 GLOBAL MARKET FORECAST FOR BRAND-NAME NOVANTRONE, THROUGH 2012 ($ MILLIONS)

 72

Table 36 GLOBAL MARKET FORECAST FOR REBIF, THROUGH 2012 ($ MILLIONS)

 73

Table 37 U.S. REBIF SALES AS A PERCENTAGE OF TOTAL SALES, 2003-2012 (PERCENT (%) ROUNDED TO THE NEAREST WHOLE VALUE)

 74

Table 38 GLOBAL MARKET FORECAST FOR TYSABRI, THROUGH 2012 ($ MILLIONS)

 76

Table 39 A SAMPLE OF MS DRUG CANDIDATES IN CLINICAL TRIALS

 78

Table 40 GLOBAL MARKET FORECAST FOR PARKINSON'S DISEASE THERAPEUTICS, THROUGH 2012 ($ MILLIONS)

 88

Table 41 GLOBAL MARKET FORECAST FOR APOKYN/APOMORPHINE, THROUGH 2012 ($ MILLIONS)

 94

Table 42 GLOBAL MARKET FORECAST FOR AZILECT, THROUGH 2012 ($ MILLIONS)

 96

Table 43 GLOBAL MARKET FORECAST FOR MIRAPEX, THROUGH 2012 ($ MILLIONS)

 97

Table 44 GLOBAL MARKET FORECAST FOR REQUIP FOR PARKINSON'S DISEASE, THROUGH 2012 ($ MILLIONS)

 99

Table 45 U.S. PD-RELEATED REQUIP SALES AS A PERCENTAGE OF TOTAL SALES, 2004-2012 (PERCENT (%) ROUNDED TO THE NEAREST WHOLE VALUE)

 100

Table 46 GLOBAL MARKET FORECAST FOR COMTAN/STALEVO, THROUGH 2012 ($ MILLIONS)

 101

Table 47 GLOBAL MARKET FORECAST FOR TASMAR, THROUGH 2012 ($ MILLIONS)

 102

Table 48 GLOBAL MARKET FORECAST FOR ZELAPAR, THROUGH 2012 ($ MILLIONS)

 104

Table 49 A SAMPLE OF PD DRUG CANDIDATES IN CLINICAL TRIALS

 105

Table 50 GLOBAL MARKET FORECAST FOR MUSCULAR DYSTROPHY-RELATED THERAPEUTIC AGENTS, THROUGH 2011 ($ MILLIONS)

 110

Table 51 MD DRUG CANDIDATES IN CLINICAL TRIALS

 114

Table 52 GLOBAL MARKET FORECAST FOR RARE NEURODEGENERATIVE DISORDERS, THROUGH 2012 ($ MILLIONS)

 117

Table 53 CANDIDATES IN CLINICAL TRIALS FOR RARE DISORDERS

 118

Table 54 ALS-RELATED TECHNOLOGY: U.S. PATENT TRENDS, 1997-2007*

 126

Table 55 ALS-RELATED PATENTS BY USE CATEGORY

 126

Table 56 ALS-RELATED PATENTS BY ASSIGNEE CATEGORY

 127

Table 57 ALS-RELATED PATENTS BY COMPANY

 129

Table 58 ALS-RELATED PATENT APPLICATIONS BY USE CATEGORY

 130

Table 59 ALS-RELATED TECHNOLOGY: U.S. PATENT APPLICATION TRENDS, 2001-2006

 131

Table 60 HUNTINGTON'S DISEASE-RELATED TECHNOLOGY: U.S. PATENT TRENDS, 1997-2007

 132

Table 61 HD-RELATED PATENTS BY USE CATEGORY

 133

Table 62 HD-RELATED PATENTS BY ASSIGNEE CATEGORY

 134

Table 63 HD-RELATED PATENTS BY COMPANY

 135

Table 64 ALZHEIMER'S DISEASE-RELATED TECHNOLOGY: U.S. PATENT TRENDS, 1997-2007

 135

Table 65 AD-RELATED PATENTS BY USE CATEGORY

 136

Table 66 AD-RELATED PATENTS BY ASSIGNEE CATEGORY

 137

Table 67 AD-RELATED PATENTS BY COMPANY

 138

Table 68 PARKINSON'S DISEASE-RELATED TECHNOLOGY: U.S. PATENT TRENDS, 1997-2007

 139

Table 69 PD-RELATED PATENTS BY USE CATEGORY

 140

Table 70 PD-RELATED PATENTS BY ASSIGNEE CATEGORY

 141

Table 71 PD-RELATED PATENTS BY COMPANY

 142

Table 72 MULTIPLE SCLEROSIS-RELATED TECHNOLOGY: U.S. PATENT TRENDS, 1997-2007

 143

Table 73 MS-RELATED PATENTS BY USE CATEGORY

 143

Table 74 MS-RELATED PATENTS BY ASSIGNEE CATEGORY

 144

Table 75 MS-RELATED PATENTS BY COMPANY

 145

Table 76 MUSCULAR DYSTROPHY-RELATED TECHNOLOGY: U.S. PATENT TRENDS, 1997-2007

 146

Table 77 MD-RELATED PATENTS BY USE CATEGORY

 147

Table 78 MD-RELATED PATENTS BY ASSIGNEE CATEGORY

 148

Table 79 MD-RELATED PATENTS BY ORGANIZATION

 149

Table 80 MUSCULAR DYSTROPHY-RELATED TECHNOLOGY: U.S. PATENT APPLICATION TRENDS, 2001-2007

 149

Table 81 MD-RELATED PATENT APPLICATIONS BY USE CATEGORY

 150

Table 82 RARE DISORDER PATENT APPLICATIONS BY DISEASE

 150

Table 83 ATAXIA-TELANGIECTASIA-RELATED PATENTS BY USE CATEGORY

 151
   

LIST OF FIGURES

  

Summary Figure:
GLOBAL MARKET FORECAST FOR BRANDED MEDICATIONS FOR NEURODEGENERATIVE DISORDERS, 2006-2012 ($ MILLIONS

 xxv

Figure 1 GLOBAL MARKET FORECAST FOR ALZHEIMER'S DISEASE PHARMACEUTICALS, 2005-2012 ($ MILLIONS)

 11

Figure 2 GLOBAL MARKET FORECAST FOR ALS THERAPEUTICS, 2005-2012 ($ MILLIONS)

 27

Figure 3 GLOBAL MARKET FORECAST FOR HUNTINGTON'S DISEASE THERAPEUTIC AGENTS, 2006-2012 ($ MILLIONS)

 50

Figure 4 GLOBAL MARKET FORECAST FOR MULTIPLE SCLEROSIS THERAPEUTICS, 2005-2012 ($ MILLIONS)

 60

Figure 5 GLOBAL MARKET FORECAST FOR PARKINSON'S DISEASE THERAPEUTICS, 2005-2012 ($ MILLIONS)

 88

Figure 6 GLOBAL MARKET FORECAST FOR MUSCULAR DYSTROPHY-RELATED THERAPEUTIC AGENTS, 2005- 2021 ($ MILLIONS)

 111

Figure 7 GLOBAL MARKET FORECAST FOR RARE NEURODEGENERATIVE DISORDERS, 2005-2012 ($ MILLIONS)

 117


CMS, P&A House, Alma Road, Chesham, Bucks. HP5 3HB, UK
Tel:     +44 (0)1494 771734
Fax:   +44 (0)1494 778994
e-mail: jenniferc@cmsinfo.com
copyright © 2005 all rights reserved

For more information about us, visit CMSinfo.

footer bar